Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Busulfan + Cyclophosphamide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Busulfan||Busulfex||Busulphan||Busulfex (busulfan) inhibits DNA replication and RNA transcription, likely through induction of DNA alkylation (PMID: 27481448). Busulfex (busulfan) in combination with cyclophosphamide is FDA approved as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for patients with chronic myelogenous leukemia (FDA.gov).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 14||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||chronic myeloid leukemia||not applicable||Busulfan + Cyclophosphamide||FDA approved||Actionable||In a clinical trial that supported FDA approval, combination of Busulfex (busulfan) and Cytoxan (cyclophosphamide) as a conditioning regimen prior to bone marrow transplantation was better tolerated and resulted in favorable 4-year probabilities of survival and event-free survival (0.86 vs 0.72) compared to Cytoxan (cyclophosphamide) plus total body irradiation in patients with chronic myeloid leukemia (PMID: 8081005).||8081005 detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT01685411||Phase 0||Busulfan + Cyclophosphamide Filgrastim Allopurinol Mycophenolate mofetil anti-thymocyte globulin Tacrolimus Levetiracetam||Busulfan and Cyclophosphamide Followed By ALLO BMT||Recruiting|